1
|
Hoffmann D, Dvorakova T, Stroobant V, Bouzin C, Daumerie A, Solvay M, Klaessens S, Letellier MC, Renauld JC, van Baren N, Lelotte J, Marbaix E, Van den Eynde BJ. Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers. Cancer Immunol Res 2019; 8:19-31. [DOI: 10.1158/2326-6066.cir-19-0040] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 06/27/2019] [Accepted: 11/15/2019] [Indexed: 11/16/2022]
|
2
|
Théate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Hervé C, Gutierrez-Roelens I, Marbaix E, Sempoux C, Van den Eynde BJ. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 2014; 3:161-72. [PMID: 25271151 DOI: 10.1158/2326-6066.cir-14-0137] [Citation(s) in RCA: 281] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tumoral resistance to immune rejection. In humans, constitutive expression of IDO1 has been observed in several tumor types. However, a comprehensive analysis of its expression in normal and tumor tissues is still required to anticipate the risks and potential benefits of IDO1 inhibitors. Using a newly validated monoclonal antibody to human IDO1, we performed an extensive immunohistochemical analysis of IDO1 expression in normal and tumor tissues. In normal tissues, IDO1 was expressed by endothelial cells in the placenta and lung and by epithelial cells in the female genital tract. In lymphoid tissues, IDO1 was expressed in mature dendritic cells with a phenotype (CD83(+), DC-LAMP(+), langerin(-), CD123(-), CD163(-)) distinct from plasmacytoid dendritic cells. Importantly, IDO1-expressing dendritic cells were not enriched in tumor-draining lymph nodes, in contrast with previously reported findings. IDO1-expressing cells were observed in a large fraction (505/866, 58%) of human tumors. They comprised tumor cells, endothelial cells, and stromal cells in proportions that varied depending on the tumor type. Tumors showing the highest proportions of IDO1-immunolabeled samples were carcinomas of the endometrium and cervix, followed by kidney, lung, and colon. This hierarchy of IDO1 expression was confirmed by gene expression data mined from The Cancer Genome Atlas database. Expression of IDO1 may be used to select tumors likely to benefit from targeted therapy with IDO1 inhibitors.
Collapse
Affiliation(s)
- Ivan Théate
- Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | - Nicolas van Baren
- Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | - Luc Pilotte
- Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | - Pierre Moulin
- Service d'anatomopathologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Pierre Larrieu
- Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | - Jean-Christophe Renauld
- Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | - Caroline Hervé
- Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | | | - Etienne Marbaix
- de Duve Institute, Université catholique de Louvain, Brussels, Belgium. Service d'anatomopathologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium. Biolibrary, Université catholique de Louvain, Brussels, Belgium
| | - Christine Sempoux
- Service d'anatomopathologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Benoît J Van den Eynde
- Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium. de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
| |
Collapse
|
3
|
Hu J, Vien LT, Xia X, Bover L, Li S. Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biol Proced Online 2014; 16:3. [PMID: 24495546 PMCID: PMC3916315 DOI: 10.1186/1480-9222-16-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2014] [Accepted: 02/01/2014] [Indexed: 11/10/2022] Open
Abstract
Background Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs) against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsible for interacting with immune surveillance cells. However, very few high-quality mAbs against Rae-1 are available for use in multiple analyses, including Western blotting, immunohistochemistry, and flow cytometry. The lack of high-quality mAbs limits the in-depth analysis of Rae-1 fate, such as shedding and internalization, in murine models. Moreover, currently available screening approaches for identifying high-quality mAbs are excessively time-consuming and costly. Results We used Rae-1–overexpressing CT26 tumor cells to generate 60 hybridomas that secreted mAbs against Rae-1. We also developed a streamlined screening strategy for selecting the best anti–Rae-1 mAb for use in flow cytometry assay, enzyme-linked immunosorbent assay, Western blotting, and immunostaining. Conclusions Our cell line–based immunization approach can yield mAbs against GPI-anchored proteins, and our streamlined screening strategy can be used to select the ideal hybridoma for producing such mAbs.
Collapse
Affiliation(s)
| | | | | | | | - Shulin Li
- Department of Pediatrics-Research, Unit 0853, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd,, Houston, TX 77030, USA.
| |
Collapse
|